RCKT - Rocket Pharmaceuticals, Inc.
| Previous Close | 16.93 |
| Open | 16.58 |
| Bid | 16.77 x 1000 |
| Ask | 16.85 x 900 |
| Day's Range | 16.58 - 17.19 |
| 52 Week Range | 10.75 - 25.96 |
| Volume | 31,633 |
| Avg. Volume | 326,993 |
| Market Cap | 850.394M |
| Beta (3Y Monthly) | 2.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.71 |
- Business Wire•4 hours ago
Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease. University of California San Diego (UCSD) Health is the initial and lead center for the Phase 1 clinical trial under the leadership of Eric Adler, M.D., Director of Cardiac Transplant and Mechanical Circulatory Support at UC San Diego Health and Professor of Medicine at University of California, San Diego School of Medicine and Barry Greenberg, M.D. Dr. Greenberg is the Director of the Advanced Heart Failure Treatment Program at UC San Diego Health and Professor of Medicine at UC San Diego School of Medicine, and is principal investigator of the trial.
- Business Wire•20 days ago
Rocket Pharmaceuticals Sponsors 3rd Annual PKD Patients’ Forum
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform clinical-stage gene therapy company, today sponsors the 3rd Annual Pyruvate Kinase Deficiency Day in Madrid, Spain, a day devoted to patients, families, clinicians and global scientific experts.
- Simply Wall St.•26 days ago
Did You Manage To Avoid Rocket Pharmaceuticals's (NASDAQ:RCKT) 19% Share Price Drop?
While not a mind-blowing move, it is good to see that the Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) share price has...
- Insider Monkey•last month
Here’s What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT)
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- Associated Press•last month
Rocket Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 43 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
- Business Wire•last month
Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
– Initiated Phase 1 Trial for FA “Process B” Using a Modified Cell Enrichment Process, Transduction Enhancers, and Commercial-Grade Vector Manufacturing and Cell Processing –
- Business Wire•last month
Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Wednesday, May 15, 2019, at 3:40p.m.
- Business Wire•2 months ago
Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting
- Biodistribution of RP-A501 Demonstrates High Concentration in Heart, the End-Organ Target in Danon Disease -
- Business Wire•2 months ago
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM)
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that the California Institute for Regenerative Medicine (CIRM) has awarded Rocket a $6.5mm CLIN2 grant award to support the clinical development of gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). The CIRM was founded in 2004 following the passing of Proposition 71 or the California Stem Cell Research and Cures Initiative, which allocated $3 billion in state funding for stem cell research conducted in California.
- Business Wire•2 months ago
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 675,000 additional shares of its common stock, at a public offering price of $17.50 per share. Rocket intends to use the net proceeds from this offering to further fund the development of its pipeline of gene therapies for rare diseases, to accelerate the buildout of in-house manufacturing capabilities, and for general corporate purposes. SVB Leerink, Evercore ISI and William Blair acted as joint-bookrunning managers for the offering.
- Benzinga•2 months ago
The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
- Business Wire•2 months ago
Rocket Pharmaceuticals Prices Public Offering of Common Stock
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $17.50 per share. Rocket has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock. All the shares in the offering are to be sold by Rocket.
- Business Wire•2 months ago
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that it has commenced an underwritten public offering of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All the shares in the offering are to be sold by Rocket.
- Business Wire•2 months ago
Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
- 4 oral presentations and 3 poster presentations focus on Rocket’s clinical and preclinical programs -
- Business Wire•3 months ago
Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces one oral poster presentation and two poster presentations at the upcoming American College of Cardiology 2019 Annual Meeting being held March 16-18, 2019 in New Orleans, LA. RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of California San Diego School of Medicine (UCSD). UCSD Health will be the initial and lead center for the planned Phase 1 clinical trial.
- Simply Wall St.•3 months ago
Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...
- Business Wire•3 months ago
Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the first patient has been dosed in the open-label, Phase 1 clinical trial of RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA). The clinical trial will evaluate “Process B” RP-L102 which incorporates a modified cell enrichment process, transduction enhancers, and commercial-grade vector manufacturing and cell processing.
- Business Wire•3 months ago
Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA)
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces a research agreement to support the clinical development of Rocket’s lentiviral vector (LVV)-based gene therapy programs in Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO) towards registrational trials. Rocket’s LVV-based gene therapy program for LAD-I, RP-L201, is in clinical development with Rocket’s European partners at the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT).
- Business Wire•3 months ago
Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights
- Three Rocket-sponsored Gene Therapy INDs Across Two Platforms Cleared in Three Months -
- Business Wire•3 months ago
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform gene therapy company, today announces participation at the following upcoming industry co
- Business Wire•4 months ago
Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today commemorates Rare Disease Day®, a day devoted to elevating public understanding of rare diseases and calling attention to the special challenges faced by patients and families. Over 7,000 rare diseases have been identified worldwide. “Our team at Rocket is motivated everyday by our goal of advancing potentially curative gene therapy treatment options on behalf of the pediatric patients and families suffering from devastating, monogenic rare diseases,” said Kinnari Patel, Pharm.D., MBA, Chief Operating Officer and Executive Vice President, Development, of Rocket.
- Business Wire•4 months ago
Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the online publication of a comprehensive literature review of published Danon disease cases in the International Journal of Cardiology, co-authored by Eric Adler, M.D., Director of Cardiac Transplant and Mechanical Circulatory Support at UC San Diego Health and Professor of Medicine at University of California San Diego School of Medicine. The manuscript entitled, “Danon Disease: Gender Differences in Presentation and Outcomes” outlines a comprehensive review of 83 published manuscripts describing cases of Danon disease, the target indication for RP-A501.
- Business Wire•4 months ago
Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City.
- Business Wire•5 months ago
Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease
Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the clearance of the Company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for RP-A501. RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of California San Diego School of Medicine.
- Business Wire•6 months ago
Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index
Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform gene therapy company, today announces that the Company has been selected for addition to the NASDAQ Biotechnology Index® .
